{{header
 | author     = Tom Reed (politician)
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 2013
 | month      = 06
 | day        = 06
 | notes      = ''{{USBill|113|H.R.|2301}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Clinical Trial Cancer Mission 2020 Act ( H.R. 2301; 113th Congress)
 | bill       = 2301
 | billtype   = hr
 | purpose    = To amend the Public Health Service Act to enhance the clinical trial registry data bank reporting requirements and enforcement measures.
 | wikipedia  =
}}

{{Center|113th CONGRESS}}


{{Center|1st Session}}


{{Center|H. R. 2301}}


{{Center|IN THE HOUSE OF REPRESENTATIVES}}


{{Center|June 6, 2013}}


{{Center|
[[w:Tom Reed (politician)|Mr. Reed]] (for himself,
[[w:Louise Slaughter|Ms. Slaughter]] , and
[[w:Chris Collins (American politician)|Mr. Collins of New York]] ) introduced the following bill; which was referred to the [[w:United States House Committee on Energy and Commerce|Committee on Energy and Commerce]] }}


{{Center|A BILL}}

To amend the Public Health Service Act to enhance the clinical trial registry data bank reporting requirements and enforcement measures.

=Section 1. Short title=

This Act may be cited as the “Clinical Trial Cancer Mission 2020 Act” .

=Sec. 2. Enhancing clinical trial registry data bank reporting requirements and enforcement measures=



==(a) Clarification that clinical trial registry data bank requirements apply regardless of trial outcomes– ==

 Section 402(j)(1)(A)(i) of the Public Health Service Act( [http://www.law.cornell.edu/uscode/text/42/282 42 U.S.C. 282(j)(1)(A)(i)] )is amended by inserting before the period at the end the following “, whether or not such a clinical trial results in a positive or negative outcome” .

==(b) Application to grants from Department of Defense– ==

 Section 402(j)(5)(A)(i) of such Act( [http://www.law.cornell.edu/uscode/text/42/282 42 U.S.C. 282(j)(5)(A)(i)] )is amended by inserting “the Department of Defense or” after “agency of” .

==(c) Enhanced enforcement– ==

 Section 402(j)(5)(A) of such Act( [http://www.law.cornell.edu/uscode/text/42/282 42 U.S.C. 282(j)(5)(A)] )is amended by adding at the end the following new clause:

<blockquote>

===(v) Enhanced enforcement– ===

After the 30-day period described in clause (iii), if the head of an agency referred to in clause (i), as applicable, verifies that a grantee has not submitted clinical trial information as described in clause (ii), with respect to an applicable clinical trial that is funded in whole or in part by a grant from the agency, such grantee—
:(I) shall not be eligible to receive any remaining funding for the grant or funding for a future Federal grant until such time as the grantee comes into compliance with all applicable reporting requirements under this subsection; and
:(II) shall be liable to the United States for repayment of any amount provided under the grant for the clinical trial for which the grantee failed to comply with such reporting requirements..
</blockquote>

{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
